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TAR DNA-binding protein 43 (TDP-43) has been identified as the major constituent of the proteinaceous 
inclusions that are characteristic of most forms of amyotrophic lateral sclerosis (ALS) and ubiquitin 
positive frontotemporal lobar degeneration (FTLD). Wild type TDP-43 inclusions are a pathological 
hallmark of >95% of patients with sporadic ALS and of the majority of familial ALS cases, and they are 
also found in a significant proportion of FTLD cases. ALS is the most common form of motor neuron 
disease, characterized by progressive weakness and muscular wasting, and typically leads to death within 
a few years of diagnosis. To determine how the translocation and misfolding of TDP-43 contribute to ALS 
pathogenicity, it is crucial to define the dynamic behavior of this protein within the cellular environment. It 
is therefore necessary to develop cell models that allow the location of the protein to be defined. We 
report the use of TDP-43 with a tetracysteine tag for visualization using fluorogenic biarsenical 
compounds and show that this model displays features of ALS observed in other cell models. We also 
demonstrate that this labeling procedure enables live-cell imaging of the translocation of the protein from 
the nucleus into the cytosol. 
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TAR DNA-binding protein 43 (TDP-43) has been identified as the major constituent of the 
proteinaceous inclusions that are characteristic of most forms of amyotrophic lateral sclerosis 
(ALS) and ubiquitin positive frontotemporal lobar degeneration (FTLD). Wild type (WT) TDP-43 
inclusions are a pathological hallmark of >95% of patients with sporadic ALS and of the majority 
of familial ALS cases, and they are also found in a significant proportion of FTLD cases. ALS is 
the most common form of motor neurone disease, characterised by progressive weakness and 
muscular wasting, and typically leads to death within a few years of diagnosis. To determine 
how the translocation and misfolding of TDP-43 contributes to ALS pathogenicity, it is crucial to 
define the dynamic behaviour of this protein within the cellular environment. It is therefore 
necessary to develop cell models that allow the location of the protein to be defined. We report 
the use of TDP-43 with a tetracysteine tag for visualisation using fluorogenic biarsenical 
compounds, and show that this model displays features of ALS observed in other cell models. 
We also demonstrate that this labelling procedure enables live-cell imaging of the translocation 






Amyotrophic lateral sclerosis (ALS) is a progressive, and ultimately fatal, neurodegenerative 
disorder that primarily affects the upper and lower motor neurons of the central nervous system 
(CNS). Symptoms of the disease are normally first observed at a focal site of onset and then 
gradually spread to contiguous regions of the nervous system over time. As is the case with a 
number of other neurodegenerative diseases, this process is accompanied by the deposition of 
insoluble inclusions of aggregated protein in the cytoplasm of affected cell types which acts as a 
pathological signature for the condition. A major component of these inclusions has been 
identified as hyperphosphorylated and ubiquitinated pathological forms of both full-length and 
proteolytic cleavage fragments of TDP-43 1-3. Interestingly, scores of additional proteins are 
found co-deposited in spinal motor neurons with various forms of TDP-43 4. 
 
Under physiological conditions, TDP-43 is a predominantly nuclear protein and, amongst other 
functions, it is involved in mRNA regulation and splicing 1-3, 5. In ALS, however, it has been found 
to mislocalise to the cytoplasm where it forms misfolded aggregates. The formation of pre-
inclusions that do not associate with ubiquitin 6 coincides with the movement of TDP-43 from the 
nucleus, and is considered to be an early aggregated species that precedes the accumulation of 
mature, ubiquitin-associated inclusions 6, 7. There is great debate surrounding the relative 
contributions to pathogenesis of the loss of functional TDP-43 from the nucleus (loss-of-
function, LOF) and of the accumulation of aggregated species with toxic properties in the 
cytoplasm (gain-of-function, GOF), although recent evidence suggests that both mechanisms 
can contribute to the disease 8. Indeed, cytoplasmic translocation and aggregation of TDP-43 
are directly associated with cell death, suggesting that the study of the initial stages of these 
processes could significantly increase our understanding of how TDP-43 contributes to the 
molecular pathology of the disease.  
 
Fluorescent labels have been employed in many live cell models to allow the observation of the 
intracellular distribution of proteins. The tetracysteine (TC) motif and biarsenical dye system 
makes use of a derivative of fluorescein, called fluorescein arsenical hairpin binder (FlAsH). 
This dye binds to a short amino acid sequence with the TC-motif, having the general structure 
Cys-Cys-Xaa-Xaa-Cys-Cys (CCXXCC, in which X denotes any amino acid) 9. Both FlAsH and a 
red-shifted variant, ReAsH, denoting resorufin arsenical hairpin binder, are commercially 
available and well characterised fluorescent dyes. These reagents are not fluorescent in their 
unbound states, but interaction with the TC motif results in a large increase in their fluorescence 
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quantum yields. Previous studies to optimise the flanking regions of the TC peptide sequence 
resulted in two 12-amino acid motifs, FLNCCPGCCMEP and HRWCCPGCCKTF, with high 
capacities to accommodate the FlAsH and ReAsH dyes 10. Such optimised TC tags can be 
genetically inserted into the target protein, allowing the FlAsH or ReAsH dye to bind with high 
specificity. A significant advantage of the TC tag compared to the use of fluorescent proteins is 
that its small size reduces the likelihood of it significantly affecting the properties of the protein 
of interest 11. This system lends itself to the visualisation of the target protein inside live cells 
because of the relatively low cytotoxicity of the dye 12. Furthermore, it has been shown that a 
variety of proteins in common mammalian cell lines, primary cortical neurons and also Gram-
negative bacteria can be labelled with FlAsH and ReAsH 13. Both reagents have been used 
successfully to report on the conformation of proteins expressed in cultured cells 14-16. In the 
context of the present study, we note that this labelling strategy has been used in cell models of 
several neurodegenerative diseases to investigate the conformational states of aberrantly 
misfolded proteins in a cellular environment 17, 18. For example, the incorporation of a TC tag into 
a variant of huntingtin (Httex1) has been used to probe the aggregation state of the protein in 
Neuro2A cells, in which the conformational properties of the monomeric form but not the 
aggregated forms, enable the TC tag to bind to ReAsH 17. In addition, transfected SH-SY5Y 
cells have been used to overexpress TC-labelled α-synuclein, allowing the dynamics and 
structural properties of the aggregates to be studied using in situ microscopy techniques 
including fluorescence recovery after photobleaching (FRAP) and confocal fluorescence 
anisotropy 18. 
 
We discuss in this paper the development of a live cell model of ALS using transiently 
transfected SH-SY5Y cells overexpressing TC tagged WT TDP-43 (HA-TDP43-TC) that allows 
direct visualisation of the protein in living cells using the biarsenical dye FlAsH. We demonstrate 
that the TC tag does not detectably alter the behaviour of TDP-43 in this cell model by 
comparing it to cells overexpressing HA-TDP-43 (HA-TDP43), a human influenza 
haemagglutinin (HA) epitope tagged TDP-43 which is a well-characterised system used 
previously to investigate the role of TDP-43 in ALS 19, 20. We show here that the HA-TDP43-TC 
model recapitulates key biochemical features of TDP-43 proteinopathies, such as association 
with stress granule markers and phosphorylation 19, 21, 22. Furthermore, we show it is possible to 
monitor noninvasively, and with spatiotemporal resolution, the cytoplasmic accumulation of 
TDP-43 concomitantly with its nuclear clearance over the course of 72 h post-transfection. 
Finally, we demonstrate that this model is amenable to time-lapse confocal microscopy, and 
5 
 
observe FlAsH labelled TDP-43 transferring from the nucleus into the cytoplasm in real time.  
 
Materials and Methods 
Construction of plasmids 
To generate the HA- and TC-tagged WT TDP-43 (HA-TDP43 and HA-TDP43-TC) sequences, 
the cDNA encoding TDP-43 was amplified from the pCMV.SPORT6.1_TDP-43 plasmid (Source 
BioScience, Nottingham, UK) by PCR using Phusion High-fidelity DNA polymerase (Thermo 
Fisher Scientific, Loughborough, UK) and primers that either incorporated the DNA sequences 
of the HA-tag and the TC-tag (TDP43-TC (forward) and TDP43-TC (reverse) primers) or which 
incorporated the HA-tag only (HA-TDP43 (forward) and HA-TDP43 (reverse)). Sequences of the 
primers are reported in Table S1 and the DNA sequences encoding HA-TDP43 and HA-TDP43-
TC are shown in Figure S1. In both cases, the primers introduced unique BamHI and XbaI sites 
at the 5’ and 3’ ends of the coding sequences respectively. These sites were used to clone the 
genes of interest into the pcDNA3.1TM(+) vector (Thermo Fisher Scientific). The constructs were 
transformed using standard heat-shock protocols into chemically competent DH5αTM E. coli 
(Thermo Fisher Scientific) and plated on LB-agar plates containing ampicillin (100 µg/mL). DNA 
was isolated using a Qiaprep Spin mini-prep or maxi-prep kit (Qiagen, Manchester, UK) 
according to the manufacturer’s instructions. Purified DNA concentrations were determined 
using a NanoDrop® ND-1000 Spectrophotometer (Thermo Fisher Scientific) and constructs 
were confirmed by DNA sequencing (Department of Biochemistry, University of Cambridge, 
UK). 
 
Cell culture and transfection 
The human neuroblastoma SH-SY5Y cell line was routinely cultured in complete growth 
medium (DMEM/F12 supplemented with 10% (v/v) FBS) in a humidified chamber at 37°C in 
95% air and 5% CO2. Cells were either chemically transfected using Lipofectamine® 2000 




Cells were plated one day before transfection in 35 mm glass bottom dishes (Ibidi, 
ThistleScientific, Glasgow, UK) such that the culture was at 70-90% confluence on the day of 
transfection. Transfections were carried out using Lipofectamine® 2000 according to the 
manufacturer’s instructions in serum free media (DMEM/F12 without FBS). Briefly, the 
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plasmid/Lipofectamine® 2000 complex was prepared at a 1:4 ratio (μg:μL). Lipofectamine® 2000 
was incubated (room temperature (RT), 5 min) in half the total volume of media before being 
mixed with the media containing the plasmid DNA, followed by further incubation (RT, 20 min). 
The complete media was aspirated from the cultured cells and replaced with the 
DNA/Lipofectamine complex in serum free media. The cells were incubated in the 
DNA/Lipofectamine-containing media (37°C. 5 h) which was then replaced with complete media, 
and the cells were incubated overnight at 37°C before being used for further experiments.  
 
Electroporation 
Two days prior to electroporation, cells were seeded into T-75 flasks with complete growth 
media such that the cells were 70–90% confluent on the day of the experiment. The cells were 
then detached with 0.25% Trypsin-EDTA (3 mL, Thermo Fisher Scientific) and washed in 
phosphate buffered saline, pH 7.4 (PBS). The cells were re-suspended in the resuspension 
buffer provided and electroporated (1,100 V, 50 ms, 1X) according to the manufacturer’s 
protocol (Neon Transfection System, Thermo Fisher Scientific). After electroporation, the cells 
were seeded in complete growth media in 6-well, or 96-well plates (Corning, Appleton Woods 
Limited, Birmingham, UK), or in 35 mm glass bottom dishes (Ibidi, Thistle Scientific), and left for 
at least 24 h before use in experiments.  
 
Immunocytochemistry  
SH-SY5Y cells overexpressing TDP-43 were grown in 35 mm glass bottomed dishes. To 
monitor the effects over time, immunocytochemistry was performed with cells at 24, 48 and 72 h 
post transfection. The cells were washed with chilled PBS and fixed with chilled 
paraformaldehyde (3.7% in PBS, 15 min). After 15 min, the cells were washed twice with chilled 
PBS (10 min) and permeabilised by incubating in chilled PBS-T (0.3% (v/v) Triton-X in PBS, 30 
min). After 30 min, the cells were blocked with BSA (5% (w/v) in PBS-T, 30 min) and washed 
twice with chilled PBS (5 min). The cells were incubated with the primary antibody (1:1000) (RT 
for 1 h or 4 °C overnight) with gentle rocking. For co-localisation experiments, cells were co-
incubated with the primary antibodies anti-HA 3F10 (Sigma Aldrich UK Ltd., Gillingham UK) and 
either phospho (403/404) TDP-43 (ProteinTech, Manchester, UK) or phospo (409/410) TDP43 
(ProteinTech), or TIA-1 C-20 (Santa Cruz Biotechnology, Heidelberg, Germany). This was 
followed by incubation with an appropriate secondary Alexa FluorTM antibody (1:1000, Life 
Technologies, Paisley, UK) (RT for 1h or 4 °C, overnight). Wheat germ agglutinin (WGA) Alexa 
FluorTM 647 conjugate (Life Technologies) treatment was done prior to permeabilisation by 
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treating the cells with a 1:500 dilution of WGA conjugate in Hank’s buffered salt solution (HBSS; 
10 min, RT). Cells were washed twice in HBSS and permeabilisation was performed with 
subsequent labelling. Cells were washed twice with chilled PBS after incubation with each of the 
primary and secondary antibodies. After washing, the cells were incubated with the nuclear 
stain Hoechst (1 μg/mL, Life Technologies) for 5 min, and the labelled cells were mounted with 
Ibidi mounting medium (Ibidi, Thistle Scientific). Imaging of the samples was performed on a 
Leica TCS SP8 Confocal Microscope (Leica Microsystems, Wetzlar, Germany) at the 
Cambridge Advanced Imaging Centre (CAIC), University of Cambridge. 
 
In-cell biarsenical dye labelling 
For the labelling of TC tagged TDP-43 (HA-TDP43-TC) overexpressed in SH-SY5Y cells, the 
TC-FlAsH™ II In-Cell Tetracysteine Tag Detection Kit from Molecular Probes (Thermo Fisher 
Scientific) was used. Transfected SH-SY5Y cells were grown in 35 mm glass bottomed dishes. 
To monitor the effects over time, in-cell FlAsH labelling was performed at 24, 48 and 72 h post 
transfection. The cells were washed twice with reduced serum Opti-MEM® without phenol red 
(Life Technologies), and incubated with FlAsH (1 μM) in Opti-MEM® (37°C, 30 min, protected 
from light). After 30 min, the cells were washed twice with 1X BAL (2, 3-dimercaptopropanol) 
buffer in Opti-MEM® (37°C, 1 h, protected from light). For live-cell imaging at each time point, 
cells were incubated with Hoechst stain (1 μg/mL) in Opti-MEM® for 5 min after the BAL buffer 
wash steps. Finally, the cells were washed with Opti-MEM® and cultured in Opti-MEM® and 
prepared for live-cell imaging. 
 
Quantification of transfection efficiency  
Cells were transfected with either HA-TDP43 or HA-TDP43-TC using Lipofectamine® 2000. 24 h 
post-transfection, the cells were fixed and immunostained with an anti-HA antibody and an 
AlexaFluor 488 secondary antibody, to detect positively transfected cells, and Hoechst nuclear 
counterstain, to visualise the total number of cells. The samples were imaged using a Leica 
TCS SP5 confocal microscope equipped with 40x HPC Fluo Tar and 63x APO oil immersion 
objectives, and a UV diode and 488 nm argon laser line to visualise the Hoechst and AlexaFluor 
488 fluorescence respectively (Leica Microsystems, Milton Keynes, UK). Three images were 
obtained at 40x magnification in different regions of the dish for each sample. Subsequent 
quantification was performed using ImageJ, using the Cell Counter plugin to count manually all 
cells stained with the anti-HA antibody or Hoechst stain. The number of cells positive for both 






Cells transfected with HA-TDP43-TC in 35 mm glass dishes were labelled with the Molecular 
Probes™ FlAsH-EDT2 dye from Invitrogen™ Life Technologies™, 24-36 h post-transfection. 
Cells were washed in Opti-MEM® (RT, 2X) followed by incubation in FlAsH-EDT2 (1 μM in Opti-
MEM®) (RT, 30 min, protected from light). The cells were washed twice in 1 X BAL buffer (in 
Opti-MEM®) (37°C, 1 h, protected from light) and imaged in Opti-MEM®. The chamber slide 
placed in a CO2-UNIT-BL Stage top heated CO2 chamber (37°C, no CO2 perfusion) 30 min prior 
to imaging, using confocal microscopy (Leica Microsystems). The inbuilt software (LAS AF, 
Leica Microsystems) was used for time-lapse imaging using the ‘Best Focus’ function at 
different locations within the dish using the ‘Mark and Find’ function (overnight, 15 min 
intervals).  
 
Quantification of depletion of nuclear fluorescence from time-lapse images 
 Each frame of the time-lapse video was analysed as an individual tiff file in ImageJ, and 
analysis was performed in the green channel of each image. A region of interest was drawn 
around the nucleus of the target cell exhibiting fluorescence using the freeform tool. ‘Set 
measurements’ was selected from the Analyze menu, and ‘area’, ‘integrated density’ and ‘mean 
gray value’ were ticked. ‘Measure’ was selected from the ‘Analyze’ menu to obtain values. The 
process was repeated for an area of the image without fluorescence to measure the background 
signal, and was performed for all frames up to 11 h of imaging, after which there was no 
difference between nuclear fluorescence and the background signal. The results were copied 
and pasted into Microsoft Excel for further analysis. Equation 1 was used to obtain a value for 
corrected fluorescence at each time point. 
 
Equation 1: 
 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 − (𝑎𝑟𝑒𝑎 𝑜𝑓 𝑟𝑒𝑔𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 ×  𝑚𝑒𝑎𝑛  𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)  
 
Comparison of the cellular location of TDP-43 in HA-TDP43 and HA-TDP43-TC following 
electroporation treatment 
Confocal images acquired from cells expressing HA-TDP43 and HA-TDP43-TC after labelling 
with an anti-HA antibody were used to determine the location of fluorescence signals by dividing 
into three categories: (1) predominantly nuclear localisation, (2) localisation in both cytoplasm 
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and nucleus and (3) predominantly cytoplasmic localisation. Fifty cells were randomly counted 
from different sample preparations and the percentage was calculated for each category. 
 
 Immunoprecipitation experiments 
Transfected cells were rinsed with PBS (10 mL) and detached using a trypsin–EDTA solution 
followed by the addition of complete growth medium to neutralise the trypsin. The cells were 
pelleted by centrifugation (4°C, 5 min, 1500 rpm) and the supernatant was removed. The cell 
pellet was washed with chilled PBS and further centrifuged (4°C, 5 min, 1500 rpm). The 
supernatant was removed, and the cell pellet was lysed with RIPA buffer (1 mL, 50 mM Tris-
HCl, pH 8.0, 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate) supplemented with EDTA-free protease inhibitor 
cocktail (Roche Diagnostics, Mannheim, Germany) for 10 min on ice, followed by centrifugation 
(4°C, 10 min, 10,000 rpm), after which the supernatant was retained for immunoprecipitation. 
PierceTM Anti-HA Magnetic Beads (Thermo Fisher Scientific, 25 μL) were washed twice with 
TBS-T (Tris-buffered saline, 0.05% (v/v) Tween 20, 300 μL), followed by a final wash with 
ddH2O; with brief vortexing between washes. The cell lysate (1 mL) was added to a 1.5 mL 
microfuge tube followed by addition of the pre-washed magnetic beads. The sample was then 
mixed and incubated (RT, 30 min, 200 rpm) with constant rotation. After incubation, the tube 
was placed into a DynaMag™-Spin Magnet stand (Thermo Fisher Scientific) and the 
supernatant containing unbound protein was collected and saved for analysis. To elute, the HA-
tagged TDP-43 bound to the magnetic beads, Pierce HA Peptide (Thermo Fisher Scientific) 
(100 μL of 2 mg/mL) was added to the bead slurry, and this was then vortexed and incubated 
(37°C, 10 min). The eluted sample was then analysed by Western blotting.  
 
Western Blotting 
SDS-PAGE was used to separate protein samples prior to western blotting. The protein sample 
(20 μL) was prepared in NuPAGE® LDS Sample Buffer (4X) (LifeTechnologies) and NuPAGE® 
Sample Reducing Agent (10X) (Life Technologies) and run on a NuPAGE® 4-12 % gradient 
Bis-Tris (Life Technologies) gel with MES running buffer (Life Technologies) (200 V, 25 min). 
The proteins were transferred from the gel to an iBlot® Transfer Stack with PVDF membrane 
(0.2 μm pore size) using the iBlot® Dry Blotting System (Life Technologies) according to the 
manufacturer’s protocol. After transfer, the PVDF membrane was blocked with 5% (w/v) dry 
skimmed milk powder in PBS with 0.05% Tween-20 (blocking buffer) (RT, 1 h, gentle agitation). 
The membrane was then incubated with primary antibodies in blocking buffer (1:1000, 4°C, 
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overnight or RT, 1 h) followed by washing four times with PBS-T (RT, 10 min). After washing, 
the membrane was incubated with AlexaFluor 488- or 594-labelled secondary antibody (1:1000, 
RT, 1 h). After incubation, the membrane was washed four times with PBS-T and imaged using 
a Typhoon 9400 laser-based scanner (GE Healthcare) at 550 V using a green (532 nm) 
excitation laser to excite AlexaFluor 594 or a blue (488 nm) laser to excite AlexaFluor 488.  
 
Results 
Transient transfection of SH-SY5Y cells to overexpress full length TDP-43 containing a C-
terminal tetracysteine-tag (TC) 
A number of TDP-43 cell models use epitope tags or fluorescent fusion proteins to distinguish 
between overexpressed TDP-43 and the endogenous protein 7, 19, 23-25. For our model, we added 
the 12 amino acid TC tag (FLNCCPGCCMEP) 10 to the C-terminus of full-length TDP-43 (Figure 
1, i). It has been established that in disease states such as ALS, C-terminal truncated fragments 
of TDP-43 are found in the inclusions 3, 26, and so we reasoned that the addition of the TC tag to 
the C-terminus of our full-length TDP-43 construct will allow us to visualise both the full-length 
and truncated fragments of TDP-43. We also incorporated an HA-epitope tag at the N-terminus 
of the protein (Figure 1, ii) in the same construct to allow an alternative means of identification 
using antibody detection 19, 23, 25, 27, 28. The HA-TDP43-TC construct was inserted into the 
mammalian expression vector, pcDNA3.1(+). Despite the tags introduced being of relatively 
small sizes (~ 1 kDa), we checked that the addition of the C-terminal TC tag did not change the 
cellular behaviour of the overexpressed WT TDP-43, by comparing our TC-tagged TDP-43 to an 
N-terminally HA-tagged full-length TDP-43 (HA-TDP43, Fig. 1, iii) construct which has been 
previously shown to have diffuse nuclear localisation in transiently transfected cells 19, 20. 
 
Figure 1. Schematic diagram illustrating i) full length wild-type TDP-43, ii) HA-TDP43-TC and iii) 
HA-TDP43 constructs. The HA-tag is denoted in black, the nuclear localisation signal (NLS) and 
nuclear export signal (NES) are shown in purple, the RNA-recognition motifs are shown in dark 
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grey, the glycine rich region is orange and the TC-tag is shown in green.  
 
The HA-TDP43 and the HA-TDP43-TC constructs were transiently transfected into SH-SY5Y 
cells using two methods: lipofection (Lipofectamine® 2000) and electroporation (Neon™ system) 
to determine which most efficiently delivers the HA-TDP43-TC plasmid into the cells. SH-SY5Y 
cells are a human neuroblastoma cell line that is well-established and extensively used in 
neurodegenerative disease models, including for studies involving TDP-43 18, 19, 25, 29, 30. We 
used this cell line for the current study as they are consistently amenable to transient 
transfection protocols and have a favourable nucleus-to-cytoplasm ratio, which allows clear 
microscopy imaging. After 24 h post transfection, the cells were fixed, permeabilised and probed 
with an anti-HA primary antibody.  For both the HA-TDP43 and HA-TDP43-TC expressing cells, 
HA-specific labelling was detected as predominantly diffuse nuclear fluorescence (Figure 2A). 
By analysing the number of positively stained cells for the two different transfection methods, we 
observed a 10% and 12% transfection efficiency for the HA-TDP43 and HA-TDP43-TC 
plasmids, respectively, using the lipofection method, and a 14% transfection efficiency for both 
plasmids with the electroporation method (Table S2). For the HA-TDP43-TC cell line, we could 
image the live cells 24 h post-transfection using the FlAsH dye (Figure 2B), finding that FlAsH-
bound protein was predominantly localised to the nucleus. It is interesting to note that for the 
lipofected cells, the FlAsH-bound HA-TDP43-TC displayed a weaker signal intensity compared 
to electroporated cells, although this was not statistically significant (n=1, two-tailed unpaired t 
test, p=0.1404) (Table S3). We proceeded with the electroporation method in light of its greater 
efficiency, using it to characterise the intracellular distribution of HA-TDP43-TC over time. To 
confirm further the presence of the full-length protein within the cells 24 h post-transfection, the 
HA-tagged proteins were isolated using immunoprecipitation (anti-HA magnetic beads) and the 
resulting samples were analysed by Western blotting (Figure 2C); similar results were observed 




Figure 2. Confocal images of SH-SY5Y cells transfected (by either electroporation or 
lipofection) to overexpress HA-TDP43 or HA-TDP43-TC, at 24 h post-transfection. A) 
immunofluorescence images generated using an anti-HA antibody and an AlexaFluor 488 
secondary antibody (green), Hoechst nuclear stain (blue) and membranes are stained with 
wheat germ agglutinin (WGA) Alexa FluorTM 647 conjugate (red), scale bars are 50 μm; B) 
fluorescence images after the addition of the FlAsH dye (24 h post-transfection). For clarity, the 
white dotted line denotes the nucleus. Images are representative of multiple independent 
experiments. C) Immunoprecipitation followed by Western blot analysis of HA-TDP43 and HA-
TDP43-TC isolated from SH-SY5Y cell lysates at 24 h post transfection. Mock transfections are 




Monitoring HA-TDP43-TC expression at different time points post-transfection with the 
FlAsH dye 
In previously reported cell models, WT TDP-43 is overexpressed and remains localised within 
the nucleus 19, 31, whereas disease-related variants show translocation of the protein from the 
nucleus to the cytoplasm where they form inclusions when monitored up to 72 h post 
transfection. When cells expressing WT TDP-43 are exposed to conditions of stress, such as by 
the addition of arsenite or through nutrient deprivation, this aberrant behaviour is also observed 
21, 22. To determine whether or not FlAsH labelling was able to identify HA-TDP-43-TC positively 
over 72 h post transfection, we compared live-cell images after the addition of the FlAsH 
reagent to HA-TDP43-TC expressing cells at 24, 48 and 72 h post-transfection. In Neon-
transfected SH-SY5Y cells expressing HA-TDP43-TC, we observed diffuse nuclear staining 24 
h post-transfection (Figure 3, 24 h). At 48 h post-transfection, however, FlAsH fluorescence was 
observed in both the nucleus and the cytoplasm (Figure 3, 48 h), and by 72 h, FlAsH labelled 
HA-TDP43-TC was predominantly in the cytoplasm and appeared as inclusions of variable size 
(Figure 3, 72 h). The cells with strong staining of cytoplasmic inclusions showed a lack of 
nuclear fluorescence. No FlAsH fluorescence was observed at any time point (24-72 h) when 
the over-expressed protein lacked the TC tag (Figure S2). Translocation of the HA-TDP43-TC 
protein had clearly occurred spontaneously in this cell model despite earlier reports that in the 
absence of exogenous stress, WT TDP-43 remains in the nucleus 32-34. We next examined 
whether this translocation was due to the C-terminal TC tag perturbing the behaviour of WT 
TDP-43 protein or if the mode of transfection had itself imposed an exogenous stress. To carry 
out this objective we used the well-characterised HA-TDP43 cell model 19 and compared results 







Figure 3. Confocal images of FlAsH bound HA-TDP43-TC in live SH-SY5Y cells at 24, 48 and 
72 h post transfection. FlAsH fluorescence images only (upper panel), or merged with bright 
field (BF) images (lower panel). The images are representative of multiple independent 
experiments. For clarity, the outline of the nuclei is indicated by dashed white lines. The white 
arrowheads indicate punctate staining of HA-TDP43-TC. Mock transfection is cells transfected 
with buffer alone. 
 
SH-SY5Y cells were transfected to express HA-TDP43 using electroporation and, similarly to 
HA-TDP43-TC, translocation of the protein was observed at 48 and 72 h post-transfection 
(Figure 4A and 4B). Comparison of the number of cells containing nuclear or cytoplasmic TDP-
43 (detected through HA-tag labelling, n=50 cells per condition) showed that the HA-TDP43 and 
the HA-TDP43-TC models both displayed similar distributions (Figure 4C & 4D). When the cells 
underwent lipofection however, much less translocation was observed in both cell models and 
at 72 h post-transfection the nuclear TDP-43 staining remained prominent (Figure S3), in 
agreement with previous studies 20, 24, 25, 27, 28. Interestingly, when the electroporation method 
was used to transiently transfect cells to overexpress EGFP-tagged TDP-43, we found that at 
48 h and 72 h post-transfection, the TDP43-EGFP fluorescence was predominantly localised in 
the nucleus (Figure S4). This predominant nuclear localisation by WT TDP43-EGFP at 48 h  





Figure 4. HA-TDP43 and HA-TDP43-TC expression and distribution in SH-SY5Y cells at 48 and 
72 h following transfection by electroporation A) Representative images of cellular TDP-43 
distribution for HA-TDP43 (A) and HA-TDP43-TC (B); scale bars are 10 μm. Merged 
immunofluorescence images generated using an anti-HA antibody (green) and Hoechst nuclear 
counterstain (blue). Histograms showing cellular location of HA-TDP43 and HA-TDP43-TC at 
(C) 48 h and (D) 72 h post-transfection. Percentages were calculated by examining cells with 
positive HA-tag labelling from 8 independent imaging experiments until 50 cells for each 
condition (A and B) were identified.  
 
HA-TDP43-TC shows co-localisation with the stress granule marker TIA-1 
To determine if the cytoplasmic inclusions observed in cells expressing HA-TDP43-TC provide a 
useful model of ALS pathogenesis, we next examined whether or not the protein had co-
localised with a marker of stress granules (SGs), dynamic RNA-containing complexes that are 
formed in the cytoplasm when cells are subjected to stress 37. SGs direct translation towards 
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proteins required for cell survival and repair, but may under pathological conditions, stabilise 
and act as scaffolds to promote recruitment and aggregation of a variety of proteins, including 
TDP-43 38, 39. SGs in cell culture are formed within minutes of stress induction, and normally 
degrade within 3 h following the cessation of stress, but persist in response to chronic stress 37. 
It has been reported that in a number of cell models, cytoplasmic TDP-43 aggregates are found 
to co-localise with stress granule markers such as TIA-1 in both cell culture models 22, 32, 40 and 
immunocytochemical analyses of ALS and FTLD-TDP tissue samples 21, 22, 41. Chronic cellular 
stress may initiate pathological TDP-43 aggregation via its promotion of the assembly of SGs, 
thereby bringing together high concentrations of aggregation prone proteins and leading to 
cytoplasmic inclusion 42. At 48 and 72 h post-transfection, we observed that cytoplasmic 
inclusions containing HA-TDP43-TC co-localised with TIA-1 (Figure 5); similar co-localisation 





Figure 5. Comparison of the co-localisation of TDP-43 and the SG marker TIA-1 between the 
HA-TDP43 and HA-TDP43-TC SH-SY5Y cell models at 48 h and 72 h post transfection using 
electroporation. Merged immunofluorescence images generated using an anti-HA antibody 
(green) and Hoechst nuclear counterstain (blue) and anti-TIA-1 staining (red). Yellow denotes 
co-localisation between HA-labelled TDP-43 and TIA-1 (white arrows). 
 
In addition to co-localisation with SG markers, phosphorylation of TDP-43 is commonly 
regarded as a hallmark feature of ALS. Using specific antibodies that recognise phosphorylated 
Ser403/404 or Ser409/410 epitopes, cytoplasmic inclusions containing phosphorylated TDP-43 
have been detected in some cell models; this is not seen, however, in many cell-lines 
expressing WT TDP-43 36, 43. We probed transfected SH-SY5Y cells expressing HA-TDP43-TC 
with antibodies specific for TDP-43 phosphorylation at either Ser403/404 or Ser409/410. In SH-
SY5Y cells transfected to express HA-TDP43 or HA-TDP43-TC, at 48 and 72 h post 
transfection, no specific fluorescence was obtained using the pSer409/410 antibody (data not 
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shown), but fluorescent cytoplasmic inclusions were detected using the pTDP-43 Ser403/404 
antibody (Figure 6).  
 
Figure 6. Comparison of co-localisation of TDP-43 using an antibody for detection of 
phosphorylation at serine 403 and 404 residues between the HA-TDP43 and HA-TDP43-TC 
SH-SY5Y cell models at 48 h and 72 h post transfection using electroporation. Merged 
immunofluorescence images generated using an anti-HA antibody (green), Hoechst nuclear 
counterstain (blue) and an anti-TDP-43 p403/404 antibody (red). Yellow denotes co-localisation 
between HA-labelled TDP-43 and TDP43-p403/404. 
 
The TC-tag cell model shows nuclear-to-cytoplasmic translocation in real-time   
Having demonstrated that the TC-tag cell model reproduces several events relevant to the 
disease process in ALS, we finally examined whether or not it is possible to monitor TDP-43 
translocating from the nucleus into the cytoplasm in real-time. Given that the mild stress induced 
by electroporation appears to stimulate translocation of HA-TDP43-TC, no additional external 
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chemicals or processes are needed to induce this process. At 24 h post-transfection, the FlAsH 
reagent was added to these cells and they were imaged using confocal microscopy for a further 
20 h (Figure 7).  
 
Initially, individual cells expressing HA-TDP43-TC show predominantly nuclear staining (Figure 
7 a), but over the time-course of the experiment (Figure 7 b onwards) these cells can be seen to 
have developed small cytoplasmic inclusions. Interestingly, even at the initial time point when 
cytoplasmic TDP-43 can be visualised (~26 h 30 min), the fluorescence signal is not diffuse but 
appears as small puncta that clearly change position in relation to the cell nucleus over time. 
They also appear to coalesce during real-time imaging, suggesting that they merge into larger 
structures, or are just in close proximity to one another (Supplementary Video S1). The 
appearance of HA-TDP43-TC in the cytoplasm coincides with a gradual decrease in nuclear 
FlAsH signal intensity (Figure 7 c onwards, Figure S5), indicating nuclear depletion of the 
labelled TDP-43. Concerns about the high background fluorescence due to endogenous 
cysteine-rich proteins and the potential cytotoxicity of biarsenical dyes have been raised 44; 
however, with the application of BAL buffer washes, we did not observe high background 
fluorescence during our live-imaging studies, and the cells imaged did not show any signs of 




Figure 7. a-f. Frames from time-lapse confocal microscopy imaging of HA-TDP43-TC 
expressing SH-SY5Y cells labelled with FlAsH dye. Imaging commenced at 24 h post-
transfection and the subsequent time points (h) shown are a) 24:00, b) 26:30, c) 28:45, d) 
29:15, e) 33:45, and f) 42:30. The inset white boxes contain zoomed images of the cell nucleus 
(zoom factor 2 x original image). The nucleus of the target cell is denoted by a dotted line and 





Together with fluorescent protein (FP) tags, the HA tag is one of the most extensively used 
labels in investigations of the role of TDP-43 in ALS 19, 24, 45. The HA-tag, however, has a 
significant limitation, in that there is a need to fix and immunostain cells in order to detect the 
labelled TDP-43, therefore making this model incompatible with live cell imaging to monitor 
intracellular processes. The FP-TDP-43 fusion systems are amenable to live cell imaging, but 
involve the incorporation of a ~27 kDa FP. Given the relative size of the FP in relation to TDP-
43 (~27 kDa versus 43 kDa), the bulkiness of the fluorescent moiety may perturb the native 
structure and function of the TDP-43 and therefore, the use of the smaller TC-tag in conjunction 
with biarsenical dyes (~1 kDa) may prove advantageous. 
 
In this paper we have described a cell model in which the cells are transiently transfected to 
overexpress HA-tagged TDP-43 with a C-terminal TC tag, which is visualised using the 
biarsenical dye, FlAsH. This model can be used to monitor the translocation of TDP-43 from the 
nucleus to the cytoplasm in live cells using time-lapse microscopy. Although our study shows 
that the HA-TDP43-TC model is very similar to the well-characterised HA-TDP43 cell model, the 
properties of the TC tag and FlAsH make it a very valuable tool for monitoring the intracellular 
distribution of TDP-43 in live cells. The TC tag itself is relatively small, while the FlAsH dye is 
membrane permeable and non-fluorescent until it binds to the TC tagged protein. In addition, 
the dye itself is sufficiently photostable, and shows low toxicity, to allow imaging in live cells over 
several hours 13.  
 
Comparisons between the HA-TDP43-TC and HA-TDP43 cell models indicate that the C-
terminal TC tag does not detectably alter the properties of HA-TDP-43 when overexpressed in 
SH-SY5Y cells. When transfected by electroporation, at 48 and 72 h post-transfection, cells 
expressing either HA-TDP43 or HA-TDP43-TC both show cytoplasmic translocation and 
accumulation of the overexpressed protein. Interestingly, this observation differs from most 
previous reports in which WT HA-TDP43 or GFP-TDP43 has been overexpressed in transfected 
mammalian cell lines 20, 46. Nuclear to cytoplasmic translocation is more commonly observed in 
cell models expressing TDP-43 containing familial ALS mutations 47, 48 or truncated forms of the 
protein 25, 31. For cells expressing WT TDP-43, translocation of the protein to the cytoplasm has 
generally been reported to occur only following the application of external stress 21, 32. For cells 
expressing HA-TDP43 or HA-TDP43-TC, we observe predominantly nuclear localisation when 
cells were lipofected, with much less cytoplasmic TDP-43 detected at all the time points 
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measured post-transfection, than in cells transfected using electroporation. These results 
suggest that the electroporation method, which slightly increases the transfection efficiency (by 
2-4%), may also result in a degree of cell stress 49; we therefore took advantage of this 
phenomenon to study the translocation of WT TDP-43 in the absence of pharmacological 
stressors. 
 
Cells transfected by electroporation to express HA-TDP43-TC demonstrate some key 
biochemical hallmarks of ALS, including the nuclear to cytoplasm translocation, an increase in 
the appearance and size of cytoplasmic inclusions over time, an indication that the TDP-43 is at 
least partially phosphorylated and the association of the TDP-43 inclusions with TIA-1, a marker 
of stress granules 1, 3, 38. Phosphorylation of TDP-43 at the Ser403/404 or Ser409/410 epitopes 
has also been associated with ALS pathogenesis 43, 50, 51. It is not clear whether phosphorylation 
of TDP-43 leads to aggregate formation and/or neurotoxicity, or if this process represents a 
normal reaction to the presence of an intracellular aggregate, as reports have shown that 
phosphorylation of WT-TDP43 is not always observed 20, 24. We did, however, observe positive 
staining with the antibody specific for p403/404 but not the antibody specific for p409/410 (Fig. 
6).  
 
Using cells expressing HA-TDP43-TC, we were able to observe translocation of WT TDP-43 in 
the absence of pharmacological stresses in live cells over time, as indicated by the appearance 
of fluorescent motile cytoplasmic puncta together with decreased nuclear fluorescence. This 
process is thought to precede the deposition of cytoplasmic inclusions, which may contribute to 
the pathogenesis of ALS due to depletion of TDP-43 in the nucleus, preventing the protein from 
carrying out its normal regulatory functions on mRNA (LOF), and/or to the accumulation of 
cytoplasmic TDP-43 with inherently toxic properties (GOF) 52. 
 
The HA-TDP43-TC cell model shares many features of the well-established HA-TDP43 model, 
which has been successfully utilised to investigate many aspects of TDP-43-mediated disease 
processes, but offers the considerable advantage of being compatible with live cell imaging. In 
particular, we were able to monitor the nuclear to cytoplasmic translocation of TDP-43 in live 
cells using confocal microscopy, which represents an early stage in the deposition of 
aggregated TDP-43 in the cytoplasm of affected cells.  
 
Having shown that it is possible to image TDP-43 translocation in real-time using this model, it is 
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clear that this has the potential to provide quantitative information about the translocation 
process itself, and could even be applied to gain further insights into other processes, which 
occur subsequently to nuclear translocation, such as the aggregation of TDP-43 within the 
intracellular environment. This in turn may help develop a better understanding of how TDP-43 
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Supplementary methods  
Transfection efficiency  
SH-SY5Y cells expressing HA-TDP43 or HA-TDP43-TC were fixed and immunostained with 
anti-HA antibody and nuclear counterstain Hoechst, 24 h post-transfection (via lipofection or 
electroporation). These samples were then imaged using confocal microscopy at 40x 
magnification, and the number of green (HA-TDP43 or HA-TDP43-TC) and blue (Hoechst) 
stained cells present in each image were manually counted using the Cell Counter plug-in in 
ImageJ. The transfection efficiency was calculated as the number of green transfected cells 
as a percentage of the total number of blue Hoechst-stained cells counted in each image.  
 
Quantification and comparison of nuclear FlAsH fluorescence in cells transfected with 
the HA-TDP43-TC plasmid using either lipofection or electroporation  
SH-SY5Y cells were transfected with HA-TDP43-TC using both lipofection and 
electroporation methods and imaged using confocal microscopy 24 h post-transfection. The 
nuclear fluorescence in transfected cells was quantified as described in the methods section. 
A two-tailed unpaired Student t-test was performed on the mean fluorescence for each 
transfection method using GraphPad Prism version 7 for Mac OS X (GraphPad Software, La 
Jolla California USA) to determine whether or not there was a significant difference in the 
intensity of nuclear fluorescence between the two different transfection methods. 
Supplementary tables and figures 






















Table S2. Transfection efficiency of SH-SY5Y cells transfected with HA-TDP43 or HA-












264 2648 9.97 
 Electroporation 
 
53 374 14.17 
HA-TDP43-TC Lipofection 
 
236 1947 12.12 
 Electroporation 44 312 14.10 
 
 
Table S3. Nuclear fluorescence values from SH-SY5Y cells expressing HA-TDP43-TC using 
both lipofection and electroporation methods 24 h post-transfection. 
 
 HA-TDP43-TC lipofection  
Area of measurement Integrated density Nuclear fluorescence 
92.364 2574.874 2252.985 
82.204 1430.486 1144.005 
104.14 1566.261 1203.333 
96.982 1213.431 875.449 
63.731 1621.448 1399.346 
54.957 2458.034 2266.509 
60.96 881.151 668.705 
78.059 1216.663 943.059 




Area of measurement Integrated density Nuclear fluorescence 
78.509 1636.226 1335.327 
65.347 2008.453 1757.999 
94.673 2441.639 2078.789 
111.76 1719.123 1290.784 
99.522 4858.802 4477.367 






Figure S1. DNA sequences encoding A) HA-TDP43 and B) HA-TDP43-TC. Restriction 
enzyme sites (BamHI and XbaI) appear as underlined bold text. The DNA sequence 
encoding the HA-tag is highlighted yellow in A) and B), and the DNA sequence encoding the 







Figure S2. Confocal images showing HA-TDP43 (no TC-tag) in live SH-SY5Y cells at 24, 48 
and 72 h post-transfection in the presence of FlAsH reagent (middle panels). No FlAsH 
signal is detected in the absence of the TC-tag. Bright field and Hoechst nuclear 






Figure S3. Confocal images showing the distribution of HA-TDP43 and HA-TDP43-TC in 
lipofected SH-SY5Y cells at 24, 48 and 72 h post-transfection, immunostained with anti-HA 
antibody (green). The inset white boxes contain zoomed images of the cell nucleus (zoom 
factor 2 x original image).  
 
 
Figure S4. Confocal images showing the distribution of TDP43-GFP (green) in 
electroporated SH-SY5Y cells at 24, 48 and 72 h post-transfection. Cells were transfected 
with a pcDNA4/TO-TDP43-EGFP construct (GenScript, Piscataway, NJ USA) using 








Figure S5. Histogram showing the loss of nuclear fluorescence over 11 h, using HA-TDP43-
TC expressing SH-SY5Y cells labelled with FlAsH dye 24 h post-transfection using 
electroporation. Corrected total nuclear fluorescence was measured using ImageJ and 











Figure S5. Full western blot from Figure 2, panel C. Western blot analysis following 
immunoprecipitation purification of HA-TDP43 and HA-TDP43-TC from SH-SY5Y cell lysates 
at 24 h post transfection. Mock transfection is cells transfected with buffer alone. 
 
Supplementary Video S1. Time-lapse confocal microscopy video of HA-TDP43-TC 
expressing SH-SY5Y cells labelled with FlAsH dye. Imaging commenced at 24 h post-
transfection using electroporation. 
 
 
 
 
 
 
 
